India's Lupin launches generic TriCor in U.S.
MUMBAI Nov 20 (Reuters) - Indian drugmaker Lupin Ltd said on Tuesday it launched a generic version of Abbott Laboratories' cholesterol lowering drug TriCor in the United States.
Lupin got its generic fenofibrate drug approved by the U.S. Food and Drug Administration last December.
Tricor tablets have annual sales of $1.26 billion in the United States, Lupin said in a statement.
Valued $4.46 billion, shares in Lupin closed 1.11 percent up at 568.15 rupees on Tuesday, when the Mumbai stock market was almost flat.
- Judge rejects strict limits on U.S. nurse who treated Ebola patients |
- Test flight of Virgin Galactic spaceship ends in fatal crash in California
- Suspect in Pennsylvania police ambush denied bail |
- Dow, S&P 500 end at record highs; BoJ move adds fuel to rally |
- Judge issues order enforcing Ebola isolation of defiant Maine nurse